@article{08d8dd060de5413f96838b2ca0c69d66,
title = "Ocular surface disease is common in moderate-to-severe atopic dermatitis patients",
keywords = "atopic dermatitis, goblet cell, ocular surface disease",
author = "Achten, \{Roselie E\} and Bakker, \{Daphne S\} and \{van Luijk\}, \{Chantal M\} and \{van der Wal\}, \{M Marlot\} and \{de Graaf\}, Marlies and \{van Wijk\}, Femke and Zuithoff, \{Nicolaas P A\} and \{van der Rijst\}, \{Lisa P\} and Boesjes, \{Celeste M\} and Thijs, \{Judith L\} and \{de Boer\}, \{Joke H\} and \{de Bruin-Weller\}, \{Marjolein S\}",
note = "Funding Information: Roselie E. Achten has nothing to disclose. Daphne S. Bakker is a speaker for Sanofi Genzyme and LEO Pharma. Chantal M. van Luijk is a speaker for Sanofi Genzyme and Santen. Marlot van der Wal has nothing to disclose. Marlies de Graaf is a principal investigator and advisory board member and/or speaker for Sanofi Genzyme and Regeneron Pharmaceuticals and LEO Pharma. Femke van Wijk is a speaker and/or consultant for Janssen, Johnson \& Johnson and Takeda. Nicolaas P.A. Zuithoff has nothing to disclose. Lisa P. van der Rijst has nothing to disclose. Celeste M. Boesjes has nothing to disclose. Judith L. Thijs is a speaker for Sanofi Genzyme and LEO Pharma. Joke H. de Boer received research funding from Abbvie; this is outside the submitted work. Marjolein S. de Bruin‐Weller is a consultant, advisory board member and/or speaker for AbbVie, Almirall, Aslan, Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron and Sanofi‐Genzyme. ",
year = "2022",
month = jun,
doi = "10.1111/cea.14127",
language = "English",
volume = "52",
pages = "801--805",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",
}